Western-blot validation of some proteins such as ER chaperone GRP94 and EMT marker vimentin were consistent with the results in proteomic analysis. In addition, GRP94 expression was associated with tumor size and clinical staging of gastric cancer patients. Conclusion: This
study represents the first successful application of iTRAQ technology using three MDR cell lines in gastric cancer. A group of multidrug resistance related proteins in gastric cancers was identified. Among them, GRP94 may play a positive role in chemotherapy. These proteins are valuable for further study of the mechanisms of MDR in gastric cancer and may serve as prognostic markers and potential molecular targets for gastric cancer. Key Word(s): 1. gastric cancer; 2. multidrug resistance; 3. iTRAQ; 4. GRP94; Presenting Author: JING ZHANG Additional Authors: HAO HU, SHUHUI LIANG, JIE DING, KAICHUN WU, BIAOLUO WANG Corresponding MAPK inhibitor Author: JIE DING, KAICHUN WU, BIAOLUO WANG Affiliations: BAY 80-6946 molecular weight Xijing Hospital of Digestive Diseases Objective: Targeted radiopharmaceutical is an effective treatment for solid tumors. By labeling with radionuclides, targeting peptide could achieve both noninvasive diagnosis and targeted radionuclide therapy. In
order to evaluate the potential applicability of GEBP11 peptides in diagnosis and radiotherapy of gastric cancer, in this study, iodine 131 labeled GEBP11 peptides, including a novel bifid PEGlylated GEBP11 trimer and its corresponding monomer, were developed. Methods: The clinical potential of GEBP11 peptides, such as tumor binding
MCE affinity and antitumor efficacy were demonstrated and assessed with multimodality imaging methods. Results: Cerenkov and SPECT imaging showed higher tumor uptake for 131I-2PEG-(GEBP11)3 (P < 0.05, day 1; P < 0.01, day 2; vs. monomer) (fig. 1b). Key Word(s): 1. vasculature target; 2. trimeric peptide; 3. target imaging; 4. gastric cancer; Presenting Author: HUAMING AI Additional Authors: Corresponding Author: HUAMING AI Affiliations: Wuhan university Objective: Mina53 (Myc-induced nuclear antigen 53) is a novel gene, it encodes a protein with a molecular mass of 53 kDa. This article aims to study the expression of Mina53 and PCNA and their correlations with clinicopathological characteristics such as TNM stage, differentiation, lymph node metastasis, sex and age as well as the interaction between two proteins. Discuss the role of Mina53 in pancreatic cancers and try to provide a new marker or target in pancreatic diagnosis and treatment. Methods: The expression of Mina53 and PCNA were detected by immunohistochemistry method in 68 pancreatic cancer tissues, 7 chronic inflammation pancreatic tissues and 5 normal tissues, and analyze the correlation of the two proteins. Results: The positive rate of Mina53 was 76.